Company news
Prescient Therapeutics Limited news in 2016
Prescient Therapeutics Limited's news releases, calls and decks from 2016, newest first.
First Patient Dosed on Phase 1b/2 AML Trial
December 13, 2016
Phase 1b/2 Ovarian Trial Commences 2nd Dose Escalation
December 8, 2016
September 2016 Appendix 4C - Quarterly
October 28, 2016
First patient at Moffitt dosed in Phase 1b/2 breast trial
September 26, 2016
Appendix 4E and 2016 Annual Report
August 31, 2016
USPTO Grants Allowances for Two PTX-200 Patents
August 4, 2016
Change to exercise price of options
July 20, 2016
June 2016 Appendix 4C - Quarterly
July 19, 2016
Yale Joins PTXs Phase 1b/2 AML Clinical Trial
June 15, 2016
Replacement Entitlement Offer Prospectus
June 3, 2016
Offer Document
May 18, 2016
PTX Secures $7.0M Capital Raising
May 17, 2016
March 2016 Appendix 4C - Quarterly
April 21, 2016
Executive Management Change
March 30, 2016
Virax Rights Offer Documentation - 25 May 2011
March 30, 2016
VIR201 HIV Vaccine published in AIDS Journal
March 30, 2016
Update on VIR201 HIV Vaccine Clinical Trial
March 30, 2016
Terms Sheet - Skin Cancer
March 30, 2016
Exclusive License with Transgene for Novel Skin Cancer Immun
March 30, 2016
Appendix 4E
March 30, 2016
Appendix 4D (31 Dec 2010) - 25 February 2011
March 30, 2016
TG1042 Update - Melanoma
March 30, 2016
TG1042 Batch Manufacturing Completed - 26 July 2011
March 30, 2016
Suspension from Official Quotation - VHLG
March 30, 2016
Rights Offer - 19 July 2011
March 30, 2016
Dutchess Continuous Investment Agreement - 10 January 2012
March 30, 2016
Virax to acquire advanced cancer platform from Yale Uni
March 30, 2016
Response to ASX Aware Letter
March 30, 2016
Reinstatement to Official Quotation - 19 November 2013
March 30, 2016
Intellectual Property Report Update
March 30, 2016
Virax Option to Acquire Exclusive Worldwide Licence
March 30, 2016
Virax Holdings Appendix 4E and 2014 Financial Report
March 30, 2016
VHL completes Pathway acquisiton, appoints new director
March 30, 2016
Disclosure Document
March 30, 2016
Co-X-Gene Development Pipeline
March 30, 2016
Appointment of Managing Director to Drive Cancer Programs
March 30, 2016
Appendix 4C - quarterly
March 30, 2016
US FDA Reactivates PTXs IND for PTX-100 Breast Cancer Trial
March 30, 2016
Two new Patents granted to Protect Lead Asset PTX-200
March 30, 2016
PTX Acquires Worldwide License for Cancer Biomarker p27
March 30, 2016
PTX-200 Phase 1B/2 Clinical Trial Update
March 30, 2016
Proposed Grant of Options to Non-Executive Directors
March 30, 2016
Prescient Therapeutics Granted Key U.S. Patents
March 30, 2016
Prescient Appendix 4E and 2015 Annual Report
March 30, 2016
March 2015 Appendix 4C - Quarterly
March 30, 2016
June 2015 Appendix 4C - Quarterly
March 30, 2016
IND for Phase 1b/2 Ovarian Cancer Trial Transferred to PTX
March 30, 2016
Encouraging Pre-Clinical Data Presented at US Cancer Meeting
March 30, 2016
December 2014 Appendix 4C - quarterly
March 30, 2016
Approval received to transfer IND Sponsorship for PTX-200
March 30, 2016
Decks in 2016
- Rodman & Renshaw 18th Annual Global Investment Conference (September 2016)
Conference · 33 slides · Sep 13, 2016
- Investor Presentation (April 2016)
Investor deck · 28 slides · Apr 13, 2016